

ABSTRACT

2
A

Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

10030203.123104
A

In the claims:

Please amend claims 1, 6, 9, 13 to 15, 19 and 20 to read as follows:

1. A composition useful in the treatment of pathological conditions characterized by neovascularization comprising an immunoconjugate protein having an effector domain which can induce a cytolytic immune response or cytotoxic effect against a targeted cell, conjugated to a targeting domain which is a mutant form of factor VII that binds to tissue factor and has reduced blood coagulation activity.
- 5

- A4
6. A composition according to claim 1 wherein the immunoconjugate protein is encoded as a secreted molecule in an expression vector.

- A5
9. A method for treating a disease associated with neovascularization, which comprises administering to a patient having the disease an effective amount of at least one type of immunoconjugate protein having an effector domain which can induce a